<p>根据 Donoghue Forlines LLC 最近向证券交易委员会提交的文件，该公司在第一季度购买了 Eli Lilly and Company（纽约证券交易所代码：LLY - 免费报告）的新股份。这家机构投资者购买了 2,737 股该公司的股票，价值约为 2,261,000 美元。</p>
<p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<ul>
<li>特朗普 GLP-1 试点计划可能会推动诺和诺德和 Eli Lilly 的增长</li>
</ul>
<p>其他几家大型投资者也对该公司的持股进行了调整。WestEnd Advisors LLC 在第一季度将其在 Eli Lilly and Company 的持股增加了 210.0%。WestEnd Advisors LLC 现在拥有 31 股该公司的股票，价值 26,000 美元，此前在该期间又购买了 21 股。Citizens National Bank Trust Department 在第一季度将其在 Eli Lilly and Company 的持股提高了 180.0%。Citizens National Bank Trust Department 现在拥有 42 股该公司的股票，价值 35,000 美元，此前在该期间又购买了 27 股。Financial Gravity Asset Management Inc.在第一季度购买了 Eli Lilly and Company 的新股份，价值约为 40,000 美元。Mascagni Wealth Management Inc.在第四季度购买了 Eli Lilly and Company 的新股份，价值 43,000 美元。最后，O Brien Wealth Partners LLC 在第一季度将其在 Eli Lilly and Company 的持股增加了 25.5%。O Brien Wealth Partners LLC 现在拥有 59 股该公司的股票，价值 49,000 美元，此前在上个季度又购买了 12 股。机构投资者和对冲基金持有该公司 82.53% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究公司最近对 LLY 发表了评论。摩根士丹利在 7 月 10 日的报告中重申了 “增持” 评级，并将 Eli Lilly and Company 的目标股价设定为 1,135.00 美元（上调自 1,133.00 美元）。富国银行在 5 月 1 日的报告中重申了对 Eli Lilly and Company 的 “增持” 评级。汇丰全球研究在 4 月 28 日的报告中将 Eli Lilly and Company 的评级从 “强力买入” 下调至 “适度卖出”。Cantor Fitzgerald 在 4 月 22 日的报告中开始覆盖 Eli Lilly and Company 的股票。他们给予了 “增持” 评级，并设定了 975.00 美元的目标价。最后，Wall Street Zen 在 7 月 26 日的报告中将 Eli Lilly and Company 的评级从 “持有” 上调至 “买入”。一位研究分析师对该股票给予了卖出评级，五位分析师给予了持有评级，十七位分析师给予了买入评级。根据 MarketBeat 的数据，Eli Lilly and Company 目前的平均评级为 “适度买入”，平均目标价为 990.89 美元。</p>
<ul>
<li>Eli Lilly 在财报发布后的 14% 下滑是否是买入机会？</li>
</ul>
<p><strong>查看我们关于 LLY 的最新报告</strong></p>
<h2>Eli Lilly and Company 股票表现</h2>
<p>LLY 在周五开盘价为 625.15 美元。该公司的流动比率为 1.37，速动比率为 1.06，债务与股本比率为 2.18。该公司的市值为 5924.8 亿美元，市盈率为 40.86，PEG 比率为 0.91，贝塔值为 0.44。该公司的 50 日移动平均线为 774.10 美元，200 日移动平均线为 798.80 美元。Eli Lilly and Company 的 12 个月低点为 623.78 美元，12 个月高点为 972.53 美元。</p>
<ul>
<li>诺和诺德股票下跌——但底部终于到来了吗？</li>
</ul>
<p>Eli Lilly and Company（纽约证券交易所代码：LLY - 获取免费报告）最近在 8 月 7 日发布了季度财报。该公司报告每股收益（EPS）为 6.31 美元，超出分析师一致预期的 5.59 美元，超出幅度为 0.72 美元。Eli Lilly and Company 的净利润率为 25.91%，股本回报率为 98.25%。该公司本季度的收入为 155.6 亿美元，而一致预期为 144.0 亿美元。去年同期，该公司每股收益为 3.92 美元。与去年同期相比，该公司的收入增长了 37.6%。平均而言，股票研究分析师预测 Eli Lilly and Company 在当前年度将发布 23.48 美元的每股收益。</p>
<h2>Eli Lilly and Company 股息公告</h2>
<p>该公司最近还宣布了一项季度股息，将于 9 月 10 日（星期三）支付。8 月 15 日（星期五）的股东将获得每股 1.50 美元的股息。该股息的除息日期为 8 月 15 日（星期五）。这代表着每年 6.00 美元的股息和 1.0% 的收益率。Eli Lilly and Company 目前的派息比率为 48.82%。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，董事 Jamere Jackson 在 8 月 8 日（星期五）的一笔交易中购买了 200 股该股票。这些股票的平均购买价格为每股 639.56 美元，总价值为 127,912.00 美元。完成收购后，该董事直接持有 9,402 股该公司的股票，价值 6,013,143.12 美元。这笔交易代表了他们持股的 2.17% 的增加。该收购在向 SEC 的法律文件中披露，相关文件可通过 SEC 网站获取。0.13% 的股票由公司内部人士持有。</p>
<h2>Eli Lilly and Company 简介</h2>
<p>（免费报告）</p>
<p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>拥有债券的风险</li>
<li>爱彼迎超出预期盈利，但增长故事正在失去高度</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>Netflix 多头与空头：谁将在这次回调中获胜？</li>
<li>3 只前景良好的金融科技股票</li>
<li>Viasat：为什么一大笔现金让空头们纷纷逃避</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Donoghue Forlines LLC 在第一季度通过收购 2,737 股投资了 226 万美元于礼来公司（NYSE: LLY）。其他机构投资者也增加了对该公司的持股。礼来的股票获得了分析师的多次评级，平均评级为 “适度买入”，目标价格为 990.89 美元。该公司报告了强劲的季度收益，超出预期，并宣布每股派发 1.50 美元的季度股息，支付日期为 9 月 10 日</p>

<p>Donoghue Forlines LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,737 shares of the company's stock, valued at approximately $2,261,000.</p>
<div class="lb-trans"><p>根据 Donoghue Forlines LLC 最近向证券交易委员会提交的文件，该公司在第一季度购买了 Eli Lilly and Company（纽约证券交易所代码：LLY - 免费报告）的新股份。这家机构投资者购买了 2,737 股该公司的股票，价值约为 2,261,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><ul>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普 GLP-1 试点计划可能会推动诺和诺德和 Eli Lilly 的增长</li>
</ul>
</div><p>Several other large investors have also made changes to their positions in the company. WestEnd Advisors LLC grew its holdings in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the period. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $43,000. Finally, O Brien Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者也对该公司的持股进行了调整。WestEnd Advisors LLC 在第一季度将其在 Eli Lilly and Company 的持股增加了 210.0%。WestEnd Advisors LLC 现在拥有 31 股该公司的股票，价值 26,000 美元，此前在该期间又购买了 21 股。Citizens National Bank Trust Department 在第一季度将其在 Eli Lilly and Company 的持股提高了 180.0%。Citizens National Bank Trust Department 现在拥有 42 股该公司的股票，价值 35,000 美元，此前在该期间又购买了 27 股。Financial Gravity Asset Management Inc.在第一季度购买了 Eli Lilly and Company 的新股份，价值约为 40,000 美元。Mascagni Wealth Management Inc.在第四季度购买了 Eli Lilly and Company 的新股份，价值 43,000 美元。最后，O Brien Wealth Partners LLC 在第一季度将其在 Eli Lilly and Company 的持股增加了 25.5%。O Brien Wealth Partners LLC 现在拥有 59 股该公司的股票，价值 49,000 美元，此前在上个季度又购买了 12 股。机构投资者和对冲基金持有该公司 82.53% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms recently commented on LLY. Morgan Stanley reiterated an &#34;overweight&#34; rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Wells Fargo &amp; Company reiterated an &#34;overweight&#34; rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Hsbc Global Res lowered shares of Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;moderate sell&#34; rating in a report on Monday, April 28th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an &#34;overweight&#34; rating and a $975.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, July 26th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $990.89.</p>
<div class="lb-trans"><p>多家研究公司最近对 LLY 发表了评论。摩根士丹利在 7 月 10 日的报告中重申了 “增持” 评级，并将 Eli Lilly and Company 的目标股价设定为 1,135.00 美元（上调自 1,133.00 美元）。富国银行在 5 月 1 日的报告中重申了对 Eli Lilly and Company 的 “增持” 评级。汇丰全球研究在 4 月 28 日的报告中将 Eli Lilly and Company 的评级从 “强力买入” 下调至 “适度卖出”。Cantor Fitzgerald 在 4 月 22 日的报告中开始覆盖 Eli Lilly and Company 的股票。他们给予了 “增持” 评级，并设定了 975.00 美元的目标价。最后，Wall Street Zen 在 7 月 26 日的报告中将 Eli Lilly and Company 的评级从 “持有” 上调至 “买入”。一位研究分析师对该股票给予了卖出评级，五位分析师给予了持有评级，十七位分析师给予了买入评级。根据 MarketBeat 的数据，Eli Lilly and Company 目前的平均评级为 “适度买入”，平均目标价为 990.89 美元。</p>
</div><ul>
<li>Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>Eli Lilly 在财报发布后的 14% 下滑是否是买入机会？</li>
</ul>
</div><p><strong>Check Out Our Latest Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 LLY 的最新报告</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 股票表现</h2>
</div><p>LLY opened at $625.15 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market cap of $592.48 billion, a price-to-earnings ratio of 40.86, a PEG ratio of 0.91 and a beta of 0.44. The company's 50 day moving average is $774.10 and its 200 day moving average is $798.80. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $972.53.</p>
<div class="lb-trans"><p>LLY 在周五开盘价为 625.15 美元。该公司的流动比率为 1.37，速动比率为 1.06，债务与股本比率为 2.18。该公司的市值为 5924.8 亿美元，市盈率为 40.86，PEG 比率为 0.91，贝塔值为 0.44。该公司的 50 日移动平均线为 774.10 美元，200 日移动平均线为 798.80 美元。Eli Lilly and Company 的 12 个月低点为 623.78 美元，12 个月高点为 972.53 美元。</p>
</div><ul>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德股票下跌——但底部终于到来了吗？</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 98.25%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the firm posted $3.92 earnings per share. The firm's revenue was up 37.6% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>Eli Lilly and Company（纽约证券交易所代码：LLY - 获取免费报告）最近在 8 月 7 日发布了季度财报。该公司报告每股收益（EPS）为 6.31 美元，超出分析师一致预期的 5.59 美元，超出幅度为 0.72 美元。Eli Lilly and Company 的净利润率为 25.91%，股本回报率为 98.25%。该公司本季度的收入为 155.6 亿美元，而一致预期为 144.0 亿美元。去年同期，该公司每股收益为 3.92 美元。与去年同期相比，该公司的收入增长了 37.6%。平均而言，股票研究分析师预测 Eli Lilly and Company 在当前年度将发布 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Dividend Announcement</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 股息公告</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 1.0%. Eli Lilly and Company's payout ratio is currently 48.82%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 9 月 10 日（星期三）支付。8 月 15 日（星期五）的股东将获得每股 1.50 美元的股息。该股息的除息日期为 8 月 15 日（星期五）。这代表着每年 6.00 美元的股息和 1.0% 的收益率。Eli Lilly and Company 目前的派息比率为 48.82%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Jamere Jackson 在 8 月 8 日（星期五）的一笔交易中购买了 200 股该股票。这些股票的平均购买价格为每股 639.56 美元，总价值为 127,912.00 美元。完成收购后，该董事直接持有 9,402 股该公司的股票，价值 6,013,143.12 美元。这笔交易代表了他们持股的 2.17% 的增加。该收购在向 SEC 的法律文件中披露，相关文件可通过 SEC 网站获取。0.13% 的股票由公司内部人士持有。</p>
</div><h2>Eli Lilly and Company Profile</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>The Risks of Owning Bonds</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>Viasat: Why a Wall of Cash Has Shorts Running for Cover</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>拥有债券的风险</li>
<li>爱彼迎超出预期盈利，但增长故事正在失去高度</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>Netflix 多头与空头：谁将在这次回调中获胜？</li>
<li>3 只前景良好的金融科技股票</li>
<li>Viasat：为什么一大笔现金让空头们纷纷逃避</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Donoghue Forlines LLC 对礼来公司（NYSE: LLY）进行了新的 226 万美元投资